Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Articles

Economic benefits, equipment availability, research results, and FDA support are driving progress in continuous processing.

Advancing Continuous Solid-Dosage Manufacturing

The new guideline replaces the previous version-CHMP/EWP/240/95 Revision 1.

EMA Revises Guideline on Clinical Development Requirements for Fixed Combination Products

Symbiosis Pharmaceutical Services is now offering a new bulk lyophilization (freeze drying) service in response to increasing demand in the manufacture of bulk intermediates and APIs by lyophilization.

Symbiosis Launches Bulk Lyophilization Service

Alexion will construct a biologics facility in Ireland that is its first outside the US.

Alexion to Build Biologics Facility in Ireland

Andrea Straka is senior technical account specialist, West Pharmaceutical Services, Inc.

This article looks at data gathered from several studies of a widely marketed chlorobutyl rubber formulation used for vial stoppers and prefilled syringes.

Sterilization Effects on Elastomers in Sterile Parenteral Drug Products

This study evaluates the impact of controlled nucleation on the ability to optimize a lyophilization cycle for a monoclonal antibody formulation.

Controlled Nucleation for a Monoclonal Antibody Formulation—A Case Study

Pall has agreed to be acquired by Danaher for $127.20 per share.

Pall to be Acquired by Danaher

With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.

Baxter BioScience Expands Oncology Business

CombiLac is a lactose-based, co-processed excipient, designed to ease oral solid dosage form development and manufacture in direct compression.

Meggle Introduces New High-Functionality Excipient

The agency publishes draft guidance answering industry questions about the Biologics Price Competition and Innovation Act.